To include your compound in the COVID-19 Resource Center, submit it here.

Lorlatinib: Phase I/II data

Data from 52 evaluable patients with ALK- or ROS1-positive advanced NSCLC in the dose-escalation Phase I portion of an open-label,

Read the full 203 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE